1-Deoxy-1-(methylamino)-D-glucitol. A derivative of sorbitol in which the hydroxyl group in position 1 is replaced by a methylamino group. Often used in conjunction with iodinated organic compounds as contrast medium.
Anti-inflammatory analgesic.
A radiopaque medium used for urography, angiography, venography, and myelography. It is highly viscous and binds to plasma proteins.
Substances that are destructive to protozoans.
A class of compounds of the type R-M, where a C atom is joined directly to any other element except H, C, N, O, F, Cl, Br, I, or At. (Grant & Hackh's Chemical Dictionary, 5th ed)
A metallic element that has the atomic symbol Sb, atomic number 51, and atomic weight 121.75. It is used as a metal alloy and as medicinal and poisonous salts. It is toxic and an irritant to the skin and the mucous membranes.
An endemic disease that is characterized by the development of single or multiple localized lesions on exposed areas of skin that typically ulcerate. The disease has been divided into Old and New World forms. Old World leishmaniasis is separated into three distinct types according to epidemiology and clinical manifestations and is caused by species of the L. tropica and L. aethiopica complexes as well as by species of the L. major genus. New World leishmaniasis, also called American leishmaniasis, occurs in South and Central America and is caused by species of the L. mexicana or L. braziliensis complexes.
A parasitic hemoflagellate of the subgenus Leishmania leishmania that infects man and animals and causes visceral leishmaniasis (LEISHMANIASIS, VISCERAL). Human infections are confined almost entirely to children. This parasite is commonly seen in dogs, other Canidae, and porcupines with humans considered only an accidental host. Transmission is by Phlebotomus sandflies.
A parasitic hemoflagellate of the subgenus Leishmania viannia that infects man and animals and causes mucocutaneous leishmaniasis (LEISHMANIASIS, MUCOCUTANEOUS). Transmission is by Lutzomyia sandflies.
A parasitic hemoflagellate of the subgenus Leishmania viannia that infects man and animals. It causes cutaneous (LEISHMANIASIS, CUTANEOUS), diffuse cutaneous (LEISHMANIASIS, DIFFUSE CUTANEOUS), and mucocutaneous leishmaniasis (LEISHMANIASIS, MUCOCUTANEOUS) depending on the subspecies of this organism. The sandfly, Lutzomyia, is the vector. The Leishmania braziliensis complex includes the subspecies braziliensis and peruviana. Uta, a form of cutaneous leishmaniasis in the New World, is caused by the subspecies peruviana.
A parasitic hemoflagellate of the subgenus Leishmania leishmania that infects man and animals including rodents. The Leishmania mexicana complex causes both cutaneous (LEISHMANIASIS, CUTANEOUS) and diffuse cutaneous leishmaniasis (LEISHMANIASIS, DIFFUSE CUTANEOUS) and includes the subspecies amazonensis, garnhami, mexicana, pifanoi, and venezuelensis. L. m. mexicana causes chiclero ulcer, a form of cutaneous leishmaniasis (LEISHMANIASIS, CUTANEOUS) in the New World. The sandfly, Lutzomyia, appears to be the vector.
A chronic disease caused by LEISHMANIA DONOVANI and transmitted by the bite of several sandflies of the genera Phlebotomus and Lutzomyia. It is commonly characterized by fever, chills, vomiting, anemia, hepatosplenomegaly, leukopenia, hypergammaglobulinemia, emaciation, and an earth-gray color of the skin. The disease is classified into three main types according to geographic distribution: Indian, Mediterranean (or infantile), and African.
Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of PNEUMOCYSTIS pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects.
Bactericidal cationic quaternary ammonium surfactant used as a topical anti-infective agent. It is an ingredient in medicaments, deodorants, mouthwashes, etc., and is used to disinfect apparatus, etc., in the food processing and pharmaceutical industries, in surgery, and also as a preservative. The compound is toxic orally as a result of neuromuscular blockade.
A commonly used x-ray contrast medium. As DIATRIZOATE MEGLUMINE and as Diatrizoate sodium, it is used for gastrointestinal studies, angiography, and urography.
An oligosaccharide antibiotic produced by various STREPTOMYCES.
Tests that demonstrate the relative effectiveness of chemotherapeutic agents against specific parasites.
A contrast medium in diagnostic radiology with properties similar to those of diatrizoic acid. It is used primarily as its sodium and meglumine (IOTHALAMATE MEGLUMINE) salts.
Measure of the number of the PARASITES present in a host organism.
A disease caused by any of a number of species of protozoa in the genus LEISHMANIA. There are four major clinical types of this infection: cutaneous (Old and New World) (LEISHMANIASIS, CUTANEOUS), diffuse cutaneous (LEISHMANIASIS, DIFFUSE CUTANEOUS), mucocutaneous (LEISHMANIASIS, MUCOCUTANEOUS), and visceral (LEISHMANIASIS, VISCERAL).
A versatile contrast medium used for DIAGNOSTIC X-RAY RADIOLOGY.
Radiography of the ventricular system of the brain after injection of air or other contrast medium directly into the cerebral ventricles. It is used also for x-ray computed tomography of the cerebral ventricles.
Antimony complex where the metal may exist in either the pentavalent or trivalent states. The pentavalent gluconate is used in leishmaniasis. The trivalent gluconate is most frequently used in schistosomiasis.
A phospholipid from the platelet membrane that contributes to the blood clotting cascade by forming a phospholipid-protein complex (THROMBOPLASTIN) which serves as a cofactor with FACTOR VIIA to activate FACTOR X in the extrinsic pathway of BLOOD COAGULATION.
A genus of flagellate protozoa comprising several species that are pathogenic for humans. Organisms of this genus have an amastigote and a promastigote stage in their life cycles. As a result of enzymatic studies this single genus has been divided into two subgenera: Leishmania leishmania and Leishmania viannia. Species within the Leishmania leishmania subgenus include: L. aethiopica, L. arabica, L. donovani, L. enrietti, L. gerbilli, L. hertigi, L. infantum, L. major, L. mexicana, and L. tropica. The following species are those that compose the Leishmania viannia subgenus: L. braziliensis, L. guyanensis, L. lainsoni, L. naiffi, and L. shawi.
Quinolines substituted in any position by one or more amino groups.
A disease characterized by the chronic, progressive spread of lesions from New World cutaneous leishmaniasis caused by species of the L. braziliensis complex to the nasal, pharyngeal, and buccal mucosa some time after the appearance of the initial cutaneous lesion. Nasal obstruction and epistaxis are frequent presenting symptoms.
A parasitic hemoflagellate of the subgenus Leishmania leishmania that infects man and rodents. This taxonomic complex includes species which cause a disease called Oriental sore which is a form of cutaneous leishmaniasis (LEISHMANIASIS, CUTANEOUS) of the Old World.
2-, 3-, or 4-Pyridinecarboxylic acids. Pyridine derivatives substituted with a carboxy group at the 2-, 3-, or 4-position. The 3-carboxy derivative (NIACIN) is active as a vitamin.
Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.
Forceful administration into a muscle of liquid medication, nutrient, or other fluid through a hollow needle piercing the muscle and any tissue covering it.
Diseases of domestic and wild horses of the species Equus caballus.
Macrolide antifungal antibiotic produced by Streptomyces nodosus obtained from soil of the Orinoco river region of Venezuela.
Substances used to allow enhanced visualization of tissues.

Low resting potential and postnatal upregulation of NMDA receptors may cause Cajal-Retzius cell death. (1/478)

Using in situ patch-clamp techniques in rat telencephalic slices, we have followed resting potential (RP) properties and the functional expression of NMDA receptors in neocortical Cajal-Retzius (CR) cells from embryonic day 18 to postnatal day 13, the time around which these cells normally disappear. We find that throughout their lives CR cells have a relatively depolarized RP (approximately -50 mV), which can be made more hyperpolarized (approximately -70 mV) by stimulation of the Na/K pump with intracellular ATP. The NMDA receptors of CR cells are subjected to intense postnatal upregulation, but their similar properties (EC50, Hill number, sensitivity to antagonists, conductance, and kinetics) throughout development suggest that their subunit composition remains relatively homogeneous. The low RP of CR cells is within a range that allows for the relief of NMDA channels from Mg2+ blockade. Our findings are consistent with the hypothesis that CR cells may degenerate and die subsequent to uncontrolled overload of intracellular Ca2+ via NMDA receptor activation by ambient glutamate. In support of this hypothesis we have obtained evidence showing the protection of CR cells via in vivo blockade of NMDA receptors with dizocilpine.  (+info)

Overexpression of the multidrug resistance-associated protein (MRP1) in human heavy metal-selected tumor cells. (2/478)

Cellular and molecular mechanisms involved in the resistance to cytotoxic heavy metals remain largely to be characterized in mammalian cells. To this end, we have analyzed a metal-resistant variant of the human lung cancer GLC4 cell line that we have selected by a step-wise procedure in potassium antimony tartrate. Antimony-selected cells, termed GLC4/Sb30 cells, poorly accumulated antimony through an enhanced cellular efflux of metal, thus suggesting up-regulation of a membrane export system in these cells. Indeed, GLC4/Sb30 cells were found to display a functional overexpression of the multidrug resistance-associated protein MRP1, a drug export pump, as demonstrated by Western blotting, reverse transcriptase-polymerase chain reaction and calcein accumulation assays. Moreover, MK571, a potent inhibitor of MRP1 activity, was found to markedly down-modulate resistance of GLC4/Sb30 cells to antimony and to decrease cellular export of the metal. Taken together, our data support the conclusion that overexpression of functional MRP1 likely represents one major mechanism by which human cells can escape the cytotoxic effects of heavy metals.  (+info)

Value of Western blotting in the clinical follow-up of canine leishmaniasis. (3/478)

Specific serum antibody levels in Leishmania infantum-infected dogs treated with a combination of glucantime and allopurinol were estimated by indirect immunofluorescence and Western blotting. The sensitivity of Western blot was greater than that obtained with immunofluorescence titration. In general, both diagnostic methods concurred with the post-treatment clinical status of the animals. Clinical improvement of successfully treated dogs was related to lower immunofluorescence titers and simpler and/or less reactive immunodetection patterns in Western blotting. The recognition, by infected dogs, of certain low molecular weight antigens, particularly one of approximately 26 kDa, was restricted to pretreatment samples and a single animal in relapse thus apparently constituting an active infection marker.  (+info)

Supraspinal neurotensin-induced antianalgesia in mice is mediated by spinal cholecystokinin. (4/478)

Intracerebral injection of neurotensin into specific brain loci in rats produces hyperalgesia due to the release of cholecystokinin (CCK) in the spinal cord. The present purpose was to show in another species that neurotensin can antagonize the antinociceptive action of morphine through the spinal CCK mechanism in mice. Neurotensin given intracerebroventricularly (i.c.v.) at doses higher than 100 ng produced antinociception in the tail flick test. However, at lower doses between 1 pg to 25 ng, neurotensin antagonized the antinociceptive action of morphine given intrathecally (i.t.), thus demonstrating the antianalgesic activity of neurotensin. The rightward shift in the morphine dose-response curve produced by i.c.v. neurotensin was eliminated by an i.t. pretreatment with CCK8 antibody (5 microl of antiserum solution diluted 1:1000). I.t. administration of lorglumide, a CCK(A)-receptor antagonist (10-1000 ng), and PD135,158, a CCK(B)-receptor antagonist (250-500 ng), also eliminated the antianalgesic action of neurotensin. Thus, the mechanism of the antianalgesic action of neurotensin given i.c.v. involved spinal CCK. This mode of action is similar to that for the antianalgesic action of supraspinal pentobarbital which also involves spinal CCK.  (+info)

Analysis of the behaviour of selected CCKB/gastrin receptor antagonists in radioligand binding assays performed in mouse and rat cerebral cortex. (5/478)

1. The previously described complex behaviour of the CCKB/gastrin receptor antagonist, L-365,260, in radioligand binding assays could be explained by a variable population of two binding sites. We have investigated whether other CCKB/gastrin receptor ligands (PD134,308, PD140,376, YM022 and JB93182) can distinguish between these sites. 2. In the mouse cortex assay, Hill slopes were not different from unity and the ligand pKI values did not differ when either [125I]-BH-CCK-8S or [3H]-PD140,376 was used as label as expected for a single site (G2). 3. In the rat cortex, where previous analysis of replicate (n=48) L-365,260 data indicated the presence of two CCKB/gastrin sites (G1 and G2), the competition data for PD134,308, PD140,376, YM022 and JB93182 could be explained by a homogeneous population of CCKB/gastrin sites because the Hill slope estimates were not significantly different from unity. However, the estimated affinity values for JB93182 and YM022 were significantly higher and that for PD134,308 was significantly lower than those obtained in the mouse cortex when the same radioligand was used. In view of our previous data obtained with L-365,260, the rat cortex data were also interpreted using a two-site model. In this analysis, SR27897 expressed approximately 9 fold, PD134,308 approximately 13 fold and PD140,376 approximately 11 fold selectivity for the G2 site. In contrast, JB93182 expressed approximately 23 fold and YM022 approximately 4 fold selectivity for the G1 site. If the two-site interpretation of the data is valid then, because of its reverse selectivity to L-365,260, JB93182 has been identified as a compound which if radiolabelled could provide a test of this receptor subdivision.  (+info)

Characterization of the binding of a novel radioligand to CCKB/gastrin receptors in membranes from rat cerebral cortex. (6/478)

1. We have investigated the binding of a novel radiolabelled CCKB/gastrin receptor ligand, [3H]-JB93182 (5[[[(1S)-[[(3,5-dicarboxyphenyl)amino]carbonyl]-2-phenylethyla mino]-carbonyl]-6-[[(1-adamantylmethyl) amino]carbonyl]-indole), to sites in rat cortex membranes. 2. The [3H]-JB93182 was 97% radiochemically pure as assessed by reverse-phase HPLC (RP-HPLC) and was not degraded by incubation (150 min) with rat cortex membranes. 3. Saturation analysis indicated that [3H]-JB93182 labelled a homogeneous population of receptors in rat cortex membranes (pKD=9.48+/-0.08, Bmax=3.61+/-0.65 pmol g(-1) tissue, nH=0.97+/-0.02, n=5). The pKD was not significantly different when estimated by association-dissociation analysis (pKD=9.73+/-0.11; n=10). 4. In competition studies, the low affinity of the CCKA receptor antagonists, L-364,718; SR27897 and 2-NAP, suggest that, under the assay conditions employed, [3H]-JB93182 (0.3 nM) does not label CCKA receptors in the rat cortex. 5. The affinity estimates obtained for reference CCKB/gastrin receptor antagonists were indistinguishable from one of the affinity values obtained when a two site model was used to interpret [125I]-BH-CCK8S competition curves obtained in the same tissue (Harper et al., 1999). 6. This study provides further evidence for the existence of two CCKB/gastrin sites in rat cortex. [3H]-JB93182 appears to label selectively sites previously designated as gastrin-G1 and therefore it may be a useful compound for the further discrimination and characterization of these putative receptor subtypes.  (+info)

Differential effects of intrathecally administered morphine and its interaction with cholecystokinin-B antagonist on thermal hyperalgesia following two models of experimental mononeuropathy in the rat. (7/478)

BACKGROUND: Cholecystokinin-B receptor activation has been reported to reduce morphine analgesia. Neuropathic pain is thought to be relatively refractory to opioids. One possible mechanisms for a reduced effect of morphine on neuropathic pain is the induction of cholecystokinin in the spinal cord by nerve injury. The authors evaluated the role of the spinal cholecystokinin-B receptor on morphine analgesia in two rat neuropathic pain models: chronic constriction injury and partial sciatic nerve injury. METHODS: A chronic constriction injury is created by placing four loosely tied ligatures around the right sciatic nerve. A partial sciatic nerve injury was created by tight ligation of one third to one half of the right sciatic nerve. All drugs were injected intrathecally 7 and 11 days after the nerve injury. The effect of the drugs was reflected in the degree of paw withdrawal latency to thermal nociceptive stimulation. The paw withdrawal latencies of injured and uninjured paws were measured 5, 15, 30, and 60 min after the drugs were injected. RESULTS: In the chronic constriction injury model, intrathecal morphine increased the paw withdrawal latencies of injured and uninjured paws. PD135158, a cholecystokinin-B receptor antagonist, potentiated the analgesic effect of morphine on injured and uninjured paws. In the partial sciatic nerve injury model, the effect of morphine on the injured paw was less potent than that on the uninjured paw, and PD135158 potentiated the morphine analgesia in the uninjured paw and had only a minor effect on the morphine analgesia in the injured paw. CONCLUSIONS: The effectiveness of morphine for thermal hyperalgesia after nerve injury depends on the type of nerve injury. The role of the cholecystokinin-B receptor in morphine analgesia in thermal hyperalgesia after nerve injury also depends on the type of nerve injury.  (+info)

Glycine-extended gastrin exerts growth-promoting effects on human colon cancer cells. (8/478)

BACKGROUND: Since human colon cancers often contain significant quantities of progastrin-processing intermediates, we sought to explore the possibility that the biosynthetic precursor of fully processed amidated gastrin, glycine-extended gastrin, may exert trophic effects on human colonic cancer cells. MATERIALS AND METHODS: Binding of radiolabeled glycine-extended and amidated gastrins was assessed on five human cancer cell lines: LoVo, HT 29, HCT 116, Colo 320DM, and T 84. Trophic actions of the peptides were assessed by increases in [3H]thymidine incorporation and cell number. Gastrin expression was determined by northern blot and radioimmunoassay. RESULTS: Amidated gastrin did not bind to or stimulate the growth of any of the five cell lines. In contrast, saturable binding of radiolabeled glycine-extended gastrin was seen on LoVo and HT 29 cells that was not inhibited by amidated gastrin (10(-6) M) nor by a gastrin/CCKB receptor antagonist (PD 134308). Glycine-extended gastrin induced a dose-dependent increase in [3H]thymidine uptake in LoVo (143 +/- 8% versus control at 10(-10) M) and HT 29 (151 +/- 11% versus control at 10(-10) M) cells that was not inhibited by PD 134308 or by a mitogen-activated protein (MAP) or ERK kinase (MEK) inhibitor (PD 98509). Glycine-extended gastrin did stimulate jun-kinase activity in LoVo and HT 29 cells. The two cell lines expressed the gastrin gene at low levels and secreted small amounts of amidated gastrin and glycine-extended gastrin into the media. CONCLUSIONS: Glycine-extended gastrin receptors are present on human colon cancer cells that mediate glycine-extended gastrin's trophic effects via a MEK-independent mechanism. This suggests that glycine-extended gastrin and its novel receptors may play a role in colon cancer cell growth.  (+info)

View more ,We sought to investigate the T1 kinetics of blood and myocardium after three infusion schemes of gadobenate dimeglumine (Gd‐BOPTA) and subsequently compared contrast‐enhanced whole‐heart coronary MRI after a bolus Gd‐BOPTA infusion with nonenhanced coronary MRI at 1.5 T. Blood and myocardium T1 was measured in seven healthy adults, after each underwent three Gd‐BOPTA infusion schemes (bolus: 0.2 mmol/kg at 2 mL/sec, hybrid: 0.1 mmol/kg at 2 mL/sec followed by 0.1 mmol/kg at 0.1 mL/sec, and slow: 0.2 mmol/kg at 0.3 mL/sec). Fourteen additional subjects underwent contrast‐enhanced coronary MRI with an inversion‐recovery steady‐state free precession sequence after bolus Gd‐BOPTA infusion. Images were compared with nonenhanced T2‐prepared steady‐state free precision whole‐heart coronary MRI in signal‐to‐noise ratio, contrast‐to‐noise ratio, depicted vessel length, vessel sharpness, and subjective image quality. Bolus and slow infusion schemes resulted in ...
METHODS: In this blinded randomized crossover study, 20 patients with known myocardial infarction underwent two separate delayed-enhancement MRI examinations after receiving 0.1 mmol/kg gadobenate dimeglumine and 0.2 mmol/kg gadopentetate dimeglumine (random administration). The conspicuity of lesion enhancement 5, 10, and 20 minutes after contrast administration was quantified as relative enhancement ratio (RER).. RESULTS: With either gadolinium-based contrast agent, damaged myocardium had higher signal intensity than normal remote myocardium (RER , 4) on delayed-enhancement MR images, and the blood RER declined over time after contrast administration. The blood RER was not significantly higher for gadobenate dimeglumine than for gadopentetate dimeglumine at 5 and 10 minutes. Nevertheless, there was a larger reduction in blood RER for gadobenate dimeglumine than for gadopentetate dimeglumine between 5 and 10 minutes and between 10 and 20 minutes. The volumes of enhancement were similar for ...
TY - JOUR. T1 - Focal liver lesions. T2 - Evaluation of the efficacy of gadobenate dimeglumine in MR imaging - A multicenter phase III clinical study. AU - Petersein, Jan. AU - Spinazzi, Alberto. AU - Giovagnoni, Andrea. AU - Soyer, Philippe. AU - Terrier, Francois. AU - Lencioni, Riccardo. AU - Bartolozzi, Carlo. AU - Grazioli, Luigi. AU - Chiesa, Antonio. AU - Manfredi, Riccardo. AU - Marano, Pasquale. AU - Van Persijn Van Meerten, Els L.. AU - Bloem, Johannes L.. AU - Petre, Carina. AU - Marchal, Guy. AU - Greco, Alina. AU - McNamara, Michael T.. AU - Heuck, Andreas. AU - Reiser, Maximilian. AU - Laniado, Michael. AU - Claussen, Claus. AU - Daldrup, Heike E.. AU - Rummeny, Ernst. AU - Kirchin, Miles A.. AU - Pirovano, Gianpaolo. AU - Hamm, Bernd. PY - 2000/6. Y1 - 2000/6. N2 - PURPOSE: To evaluate gadobenate dimeglumine (Gd-BOPTA) for dynamic and delayed magnetic resonance (MR)imaging of focal liver lesions. MATERIALS AND METHODS: In 126 of 214 patients, MR imaging was performed before ...
|i|Purpose|/i|. Retrospective comparison between gadofosveset trisodium and gadobenate dimeglumine steady state magnetic resonance angiography (SS-MRA) of the thoracic vasculature at 1.5T using signal-to-noise ratio (SNR) and vessel edge sharpness (ES) as markers of image quality. |i|Materials and Methods|/i|. IRB approval was obtained. Twenty separate patients each underwent SS-MRA using high-resolution 3D ECG-triggered coronal IR-TFE at 1.5T approximately 3-4 minutes following 10 or 15 mL gadofosveset or 20 mL gadobenate. ROIs were placed in the right atrium, left ventricle, left atrium, ascending aorta, descending aorta, and right pulmonary artery to estimate SNR. Vessel ES was estimated as 20-80% rise distances from line intensity profiles in the left pulmonary vein, ascending aorta, and descending aorta. Data were analyzed using nonpaired Students |svg xmlns:xlink=http://www.w3.org/1999/xlink xmlns=http://www.w3.org/2000/svg style=vertical-align:-0.11285pt;width:5.9250002px; id=M1 height=
Gadoterate meglumine(Dotatrem) generic is a gadolinium based contrast agent, prescribed for visualization of brain along with with magnetic resonance imaging (MRI).
Learn about the potential side effects of gadoterate meglumine. Includes common and rare side effects information for consumers and healthcare professionals.
Read the side effects of Gadoterate meglumine as described in the medical literature. In case of any doubt consult your doctor or pharmacist.
GMP grade Meglumine / CAS 6284-40-8/N-Methyl-D-glucamine,US $ 15.9 - 15.9, 6284-40-8, 6284-40-8, N-Methyl-D-glucamine, C7H17NO5.Source from N&R Bio Industries Inc. (Xian) on Alibaba.com.
A comparative study on the efficacy of combination therapy with Omeprazole and low dose systemic Meglumine Antimoniate (Glucantime) and the full dose systemic Meglumine Antimoniate in the treatment of cutaneous ...
RESULTS: One hundred fourteen of 123 enrolled patients successfully underwent both examinations. Final diagnoses were intra-axial tumors, metastases, extra-axial tumors, other tumors, and nontumor (49, 46, 8, 7, and 4 subjects, respectively). Readers 1, 2, and 3 demonstrated preference for gadobenate dimeglumine in 46 (40.7%), 54 (47.4%), and 49 (43.0%) patients, respectively, compared with 6, 7, and 7 patients for gadobutrol (P , .0001, all readers). Highly significant (P , .0001, all readers) preference for gadobenate dimeglumine was demonstrated for all other qualitative end points. Inter-reader agreement was good for all evaluations (K = 0.414 - 0.629). Significantly superior CNR and LBR were determined for gadobenate dimeglumine (P , .019, all readers).. ...
There was no detectable biotransformation of gadobenate ion. Dissociation of gadobenate ion in vivo has been shown to be minimal, with less than 1% of the free chelating agent being recovered alone in feces.. Pharmacokinetics in Special Population Renal Impairment: A single intravenous dose of 0.2 mmol/kg of MultiHance was administered to 20 subjects with impaired renal function (6 men and 3 women with moderate renal impairment [urine creatinine clearance ,30 to ,60 mL/min] and 5 men and 6 women with severe renal impairment [urine creatinine clearance ,10 to ,30 mL/min]). Mean estimates of the elimination half-life were 6.1 ± 3.0 and 9.5 ± 3.1 hours for the moderate and severe renal impairment groups, respectively as compared with 1.0 to 2.0 hours in healthy volunteers. Hemodialysis: A single intravenous dose of 0.2 mmol/kg of MultiHance was administered to 11 subjects (5 males and 6 females) with end-stage renal disease requiring hemodialysis to determine the pharmacokinetics and ...
In recent years, there have been a number of studies comparing different gadolinium chelates for MR imaging of tumors, particularly for MR imaging of intracranial neoplasms. These have included intraindividual studies that compared gadobenate dimeglumine (MultiHance; Bracco, Milan, Italy) with other gadolinium agents1-3 for imaging cerebral tumors, and a study similar to that of Kim et al4 that compared gadobutrol (Gadovist; Bayer Schering Pharma, Berlin, Germany) with gadopentetate dimeglumine (Magnevist; Bayer Schering Pharma) for imaging of cerebral metastasis.5. Studies comparing gadobenate dimeglumine with other gadolinium chelates have demonstrated the superiority of this agent in terms of contrast enhancement and lesion characterization, delineation, extension, and definition of internal structures at 1.5T and 3T. Lesions included were mostly intracranial tumors, with the highest percentage being intraparenchymal gliomas. Although detailed evaluation of different histologic types has yet ...
March 21, 2013 -- Guerbet announced that the U.S. Food and Drug Administration (FDA) has approved Dotarem (gadoterate meglumine), a gadolinium-based contrast agent (GBCA) indicated for intravenous use with magnetic resonance imaging (MRI) in brain (intracranial), spine and associated tissues in adult and pediatric patients (2 years of age and older) to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity.. Dotarem - which has been commercialized widely throughout the world since 1989 and more than 37 million doses administered[1] - is the only macrocyclic and ionic GBCA. The recommended dose is 0.2 mL/kg (0.1 mmol/kg) body weight (BW). Dotarem injection 0.5 mmol/mL contains 376.9 mg/mL of gadoterate meglumine, and is available in vials and pre?filled syringes.. This approval is a major milestone for Guerbet, which has a proud history of providing safe and effective contrast agents to patients worldwide, said Yves LEpine, CEO of Guerbet Group. ...
GE Healthcares innovative shatterproof polymer +PLUSPAK Pharmacy Bulk Package has been approved by the US FDA for use with its macrocyclic gadolinium
MilliporeSigma, a leading science and technology company, today announced the opening of a facility in Mollet des Vallès, Spain dedicated to the manufacture of meglumine, an FDA-approved excipient for pharmaceuticals and a component of medical imaging contrast media.
Delafloxacin Meglumine reference guide for safe and effective use from the American Society of Health-System Pharmacists (AHFS DI).
Gadolinium chelate that has a similar action and use than gadopentetic acid. At latest update no published data on excretion into breast milk were found. It has been used in the pediatric age. The various contrast media that are gadolinium derivatives and used for explorations with Magnetic Resonance Imaging (MRI) are considered compatible with breastfeeding because they are quickly eliminated (elimination half-life of less than 2 hours). They undergo very little metabolic changes and are virtually non-absorbable orally. They are structurally very similar to each other. Some have been shown to have no or minimal excretion into the milk (ACR 2018 p99, Wang 2012, Rubik 2000, Rofsky 1993). Less than 0.04% of the dose given to the mother ends just going into the milk (ACR 2018 p99, Wang 2012, Rubik 2000, Rofsky 1993). Due to its low oral bioavailability, intestinal absorption should be less than 1% of the dose took by the infant. The maximum dose received by the infant is considered less
Efficacy of topical 5% imiquimod with cryotherapy versus intralesional meglumine antimoniate in the treatment of anthroponotic cutaneous ...
Dotarem Project name: gadoterate meglumine Disease: Central nervous system diagnostic agent Peak sales estimate: North of $205 million Approved: March 21 Company: Guerbet The Scoop: Guerbets...
TY - JOUR. T1 - Enhancement of abdominal structures on MRI at 1.5 and 3 T. T2 - European Radiology. AU - AlObaidy,Mamdoh. AU - Ramalho,Miguel. AU - Velloni,Fernanda. AU - Matos,António P.. AU - Herman,Kevin. AU - Semelka,Richard C.. PY - 2017/4/1. Y1 - 2017/4/1. N2 - Objective: To quantitatively compare the extent of enhancement of abdominal structures on MRI in an intraindividual fashion at 1.5 and 3 T. Methods: HIPAA-compliant, retrospective, longitudinal, intraindividual, crossover study, with waived informed consent, of consecutive individuals scanned at both 1.5 and 3 T closed-bore magnets using gadobenate dimeglumine during different phases of enhancement at tightly controlled arterial phase timing. Quantitative ROI measurements and qualitative sub-phase arterial phase assignments were independently performed by two radiologists. Qualitative discrepancies were resolved by a senior radiologist. Results: Final population included 60 patients [41 female and 19 male; age, 49.35 ± 18.31 years ...
Viral infections affect three to five million patients annually. antiviral treatment, this review provides the verified data around the medicinal plants and related herbal substances ABT 492 meglumine (Delafloxacin meglumine) with antiviral activity, as well as applied strategies for the delivery of these herb extracts and biologically active phytochemicals. Open in a separate windows Graphical Abstract against most viruses, but often are ineffective in patients. Ninety different antiviral brokers available today [3, 4] only treat a selection of viruses; these viruses include HIV (human immunodeficiency computer virus), herpes viruses, including HSV (herpes simplex virus), hCMV (human cytomegalovirus), VZV (varicella zoster computer virus), influenza viruses, and the hepatitis viruses (Fig. ?(Fig.1).1). Currently, there is no approved remedy for many types or viruses, and vaccination is limited to hepatitis A computer virus, mumps, and varicella [2]. In addition, these brokers are often costly ...
WHITEHOUSE STATION, N.J.- Merck & Co., Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved EMEND (fosaprepitant dimeglumine) for Injection, a new intravenous therapy fo...
AASraw ni mtengenezaji wa uzalishaji wa wingi wa Fosaprepitant dimeglumine chini ya udhibiti wa CGMP, na hutoa mauzo ya mtandaoni, kemikali ya synthetic na iliyoboreshwa,
Evaluation of a Possible Synergistic Effect of Meglumine Antimoniate with Paromomycin, Miltefosine or Allopurinol on in Vitro Susceptibility of Leishmania tropica Resistant Isolate.
China Flunixin Injection Exporter, welcome Flunixin Meglumine Injection, Flunixin Meglumine Paste, Flunixin Meglumine For Animal purchasers from worldwide to visit our site.
Looking for antimoniate? Find out information about antimoniate. The radical - in salts derived from antimony pentoxide, Sb4O10, and bases. McGraw-Hill Dictionary of Scientific & Technical Terms, 6E, Copyright © 2003 by... Explanation of antimoniate
Gadopentetate dimeglumine (also known as MagnevistTM) is an extracellular intravenous contrast agent used in magnetic resonance imaging. linear, ionic molecule 100% renally excreted T1 relaxivity @ 1.5 T: 3.9-4.3 concentration: 0.5 mmol/mL ...
Cutaneous leishmaniasis is an endemic disease in Iran and there is no curative treatment. The disfiguring scar that remains after it subsidesis a major psychologic and emotional problem in these patients. Chronic leishmaniasisis a rare form of this malady which is seen in 5-7 percent of cases. In this article we report a 46-year-old man who was refered to us for a large leishmaniasis lesion consisting of a scaling erythematous plaque with several papules on the right side of face and nose. This patient was treated by a combination of systemic Glucantime, 50% trichlroacetic acid and oral fluconazole. Complete resolution was achieved after 4 ...
Twenty-two patients (64 ± 10.2 years) with suspected coronary artery disease underwent cardiac MR examination at 3 T (MAGNETOM Tim Trio, Siemens, Germany) after informed consent was obtained. Coronary arteries were imaged using an ECG-triggered, navigator-gated, inversion-recovery, segmented gradient-echo sequence with isotropic whole-heart coverage. A twelve-element matrix coil (six anterior and six posterior) was used for data acquisition. To speed up data acquisition, parallel acquisition (GRAPPA) was used in the phase-encoding direction with an acceleration factor of two. Imaging parameters included: voxel size 0.65 × 0.65 × 0.65 mm3 (interpolated from 1.3 × 1.3 × 1.3 mm3), TR/TE = 3.3/1.5 msec, flip angle = 20°, bandwidth = 700 Hz/pixel, imaging time = 8.8 ± 1.9 min. Contrast agent (0.2 mmol/kg body weight, Multihance, Bracco Imaging SpA, Italy) was intravenously administered at the rate of 0.3 ml/sec using a Medrad power injector. All patients received x-ray angiography (CAG) within ...
Buy Vetameg (flunixin meglumine) Injectable for Horses & Livestock, 50 mg/mL,100-mL vial at Chewy.com. FREE shipping and the BEST customer service!
TY - JOUR. T1 - Arterial visualization by contrast-enhanced moving-table MR angiography. T2 - Crossover comparison of 0.1 and 0.2 mmol/kg doses of meglumine gadopentetate in normal volunteers. AU - Hayashi, Hiromitsu. AU - Yuasa, Yuji. AU - Amano, Yasuo. AU - Tanimoto, Akihiro. AU - Saito, Yoko. AU - Yoshioka, Kunihiro. AU - Kita, Miho. AU - Kumazaki, Tatsuo. AU - Hiramatsu, Kyoichi. PY - 2008/9/1. Y1 - 2008/9/1. N2 - Purpose: To determine the appropriate dose of contrast medium for moving-table MR angiography (MT-MRA) from the abdominal aorta to the ankle by comparing visualization with different doses of meglumine gadopentetate (Gd-DTPA) administered in crossover fashion to normal volunteers. Materials and Methods: Twelve healthy adults underwent imaging after crossover administration of 0.1 and 0.2 mmol/kg of Gd-DTPA in random order. Continuous MT-MRA was performed with a fast 3D spoiled gradient echo sequence without parallel imaging technique. Visualization was evaluated in a total of 252 ...
RESULTS Considering the whole group of MR examinations performed either without (n = 26) or without and with intravenous injection of gadopentetate dimeglumine (n = 16), overall 20 MR studies were judged to show disease. Seventeen of 26 microadenomas were adequately shown and located by MR (true-positive, 65.4%). In three cases the sides of the microadenomas were misjudged (false-positive, 11.5%). Six patients had negative MR studies (false-negative, 23%). Twelve of the 16 patients studied after gadopentetate dimeglumine injection had true-positive MR findings (75%).. ...
Potassium antimonate trihydrate, >94%, Alfa Aesar™ 50g Potassium antimonate trihydrate, >94%, Alfa Aesar™ Inorganic Potassium Compounds
PURPOSE: To investigate for the first time the feasibility of aortic four-dimensional (4D) flow at 7T, both contrast enhanced (CE) and non-CE. To quantify the signal-to-noise ratio (SNR) in aortic 4D flow as a function of field strength and CE with gadobenate dimeglumine (MultiHance). METHODS: Six healthy male volunteers were scanned at 1.5T, 3T, and 7T with both non-CE and CE acquisitions. Temporal SNR was calculated. Flip angle optimization for CE 4D flow was carried out using Bloch simulations that were validated against in vivo measurements. RESULTS: The 7T provided 2.2 times the SNR of 3T while 3T provided 1.7 times the SNR of 1.5T in non-CE acquisitions in the descending aorta. The SNR gains achieved by CE were 1.8-fold at 1.5T, 1.7-fold at 3T, and 1.4-fold at 7T, respectively. CONCLUSION: The 7T provides a new tool to explore aortic 4D flow, yielding higher SNR that can be used to push the boundaries of acceleration and resolution. Field strength and contrast enhancement at all fields provide
Indomethacin,1-(4-Chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetic acid,1-(p-chlorobenzoyl)-5-methoxy-2-methyl-3-indolylacetic acid,indometacin,Bonidon,Catlep,Chrono-Indocid,Confortid,Dolcidium,Elmetacin,Idomethine,Inacid,Indacin,Indocid,Indocin,Indomed,Indomee,Indomod,Indoptic,Indoptol,Indoxen,Inflazon,Inteban,Mikametan,Rheumacin LA,Serastar,Vonum,Sodium salt trihydrate,Indomethacin Sodium salt trihydrate,Indocin I.V.,Indocid PDA,Meglumine salt,Indomethacin, Meglumine salt,Liometacen
We recently discovered that induction from the anti-inflammatory gene by cyclic AMP occurs through book cyclic AMP-dependent proteins kinase-independent systems involving activation of CCAAT/enhancer-binding proteins (C/EBP) transcription elements, notably C/EBP, from the cyclic AMP GEF EPAC1 as well as the ...
Click to predict properties on the Chemicalize site, For medical information relating to Covid-19, please consult the, ACD/Labs Percepta Platform - PhysChem Module, Compounds with the same molecular formula, Search Google for structures with same skeleton. 435.73 g/mol. Article No. FDA UNII. IF SWALLOWED: Call a POISON CENTER or doctor/physician if you feel unwell. Linear Formula: KSb (OH)6. Tel: 1-800-343-0660 or 1-978-521-6300 Molecular Weight 262.89. Insoluble in ethanol. Our site saves small pieces of text information (cookies) on your device in order to deliver better content and for statistical purposes. , Match Criteria: CAS Number. Synonyms: Potassiumhexahydroxoantimonate(V), Potassium hexahydroxoantimonate, Potassium antimonate. H6KO6Sb-2. Synonyms: Potassium antimonate. Molecular Weight: 208.85 Molecular Formula: K.O3Sb Additional Metadata ... Additional Synonyms There are no Synonyms of this type. Description: Potassium hexahydroxoantimonate(V), Analytical, Purity: >/-99.0%, CAS ...
Hexabrix contrast agent is a low osmolar ionic dimer. Each milliliter contains 393 mg of ioxaglate meglumine, 196 mg of ioxaglate sodium and 0.10 mg of edetate calcium disodium as a stabilizer. The solution contains 3.48 mg ...
AccessGUDID - DR. POYNTER AMRC (30607915132973)- Kit Contains: CA090, DIRECT DRIVE® LCA 3/BX CTS02, 5x100 Kii® SLEEVE ZTHR 12/BX CTF33, 11x100 Kii® Fios® ZTHR 6/BX CTF03, 5x100 Kii® Fios® Z-THR 6/BX CD001, 10mm RETRIEVAL SYSTEM, 10/BX CB030, 5mmx35cm EPIX® LAPA SCISSOR, 10/BX
Meglumine diatrizoate + sodium diatrizoate is used in the treatment of .get complete information about meglumine diatrizoate + sodium diatrizoate including usage, side effects, drug interaction, expert advice along with medicines associated with meglumine diatrizoate + sodium diatrizoate at 1mg.com
The effect of flunixin meglumine and flurbiprofen on the course of experimental Escherichia coli mastitis was examined. Nine cows (within one month post partum) were inoculated intramammarily with 20 x 10(5) viable E coli in both rear quarters. Three cows remained untreated (controls); three cows received three injections of flunixin meglumine and three cows received flurbiprofen as two intravenous infusions. Flunixin meglumine and flurbiprofen were initially given before clinical signs were observed. Treatment was repeated if the cows temperature increased by more than 1 degree C. In the untreated cows, rectal temperature and heart rate increased from three hours after infection, and rumen motility (both frequency and amplitude) decreased from four hours after infection. Treatment with flunixin meglumine or flurbiprofen almost completely abolished the febrile response during the first nine hours after infection, and the decrease in rumen motility was less pronounced in the treated animals. ...
Parasites isolated from patients with non-healing lesions are frequently resistant to to meglumine antimoniate, the first line of treatment in Iran.
Differential Gene Expression across Breed and Sex in Commercial Pigs Administered Fenbendazole and Flunixin Meglumine. . Biblioteca virtual para leer y descargar libros, documentos, trabajos y tesis universitarias en PDF. Material universiario, documentación y tareas realizadas por universitarios en nuestra biblioteca. Para descargar gratis y para leer online.
Flunixin meglumine is a non-steroidal anti-inflammatory medication used for treating inflammation and pain associated with musculoskeletal disease.
There are no laboratory studies available on bioaccumulation of antimony in earthworms. However, concentrations of antimony in soil and invertebrates at locations close to an antimony smelter have been measured by Ainsworth et al. (1990b). The highest antimony concentrations were found in earthworms (Oligochaeta). The dry weight concentrations (including gut contents) were 398 ± 94 mg/kg, 213 ± 65 mg/kg and 109 ± 28 mg/kg, at 100m, 250m and 450m downwind of the smelter. The EU RAR for diantimony trioxide used measurements presented in figures in Ainsworth et al.(1990b) to derive the following approximations for the 0-5, 5-10, 10-15 and ,15 cm depths for the 100m, 250m and 450m sites: 367, 253, 220 and 171 mg Sb/kg dw, 204, 155, 114 and 94 mg Sb/kg dw, and 180, 180, 163 and 135 mg Sb/kg dw, respectively. Ainsworth et al. gives earthworm body burden: soil ratios, which are 1.03, 1.05 and 0.6 for the 100m, 250m and 450m sites, respectively. Based on these data a biota-to-soil accumulation factor ...
Jinlan Pharm-Drugs Technology Co., Limited (with its export company Hangzhou Royall Import & Export Co.,Ltd.) is located in Hangzhou, Zhejiang Province. Neighboring Ningbo port, Shanghai port, Hangzhou Xiaoshan Intl Airport and Shanghai Pudong Intl Airport, the transportation and production environment are excellent. JINLAN PHARMA mainly business includes: 1) API, Pharmaceutical Intermediates, Custom Synthesis and so on. 2) Pharmaceutical Equipment such as: Distilled Water Machinery, Mixer, Sterilizer and so on. We are the biggest supplier for Contrast Agent in China such as: Iohexol, Iopromide, Ioversol, Iopamidol, Iodixanol, Iomeprol, Gadobenate Dimeglumine, Gadopentetate dimeglumine, Gadoteric acid, Gadodiamide, Caldiamide Sodium, and so on. JINLAN PHARMA focus on: Contrast Agent Vitamins API Pharmaceutical Intermediates Custom systhesis Contract manufacturing Our strongest Pharmaceutical Machines include: 1) Water Solution: Reverse Osmosis, Distilled Water Machine, Pure ...
Looking for online definition of chiclero's ulcer in the Medical Dictionary? chiclero's ulcer explanation free. What is chiclero's ulcer? Meaning of chiclero's ulcer medical term. What does chiclero's ulcer mean?
Yang Q, Li K, Liu X, Bi X, Liu Z, An J, Zhang A, Jerecic R, Li D. Contrast-enhanced whole-heart coronary magnetic resonance angiography at 3.0-T: a comparative study with X-ray angiography in a single center. J Am Coll Cardiol. 2009 Jun 30;54(1):69-76 ...
List of frequently occuring side effects for gastrografin. Sources include the official FAERS database and social media including user reviews and forum discussions.
New research published in the Nov. 21 issue of the Journal of the American College of Cardiology continues to advance the understanding of how whole-heart coronary MRI can be used to detect heart disease.. One drawback of heart MRIs is that clear images can be difficult to obtain. The hearts constant beating coupled with a patients constant breathing can blur images, rendering them unusable. Typically, images are collected during diastole. Researchers at Mie University Hospital and Matsusaka Central Hospital in Japan investigated whether image data should be collected at other times.. Researchers used whole-heart MRIs on 131 patients suspected of having coronary artery stenosis. In 48 patients, especially those with faster heart rates, the optimal time to collect data occurred while the heart was contracting rather than resting. Overall, useable images were collected in 113 patients, or 86 percent of the study participants. The study found that, for coronary arteries of at least 2 mm in ...
Bianca ALWAYS needs volunteers. The number of animals we take care of is enormous and they need treatment and walking so that they wouldnt get restless.. So, even if you have only one hour a week available, come to us and you will see that it will be rewarding. We need you to give them the help they deserve. Please show up !. ...
We use Google Ads to increase awareness for our company and to market our products. There is no advertising or marketing content from third parties on this website ...
... iothalamate meglumine and iodipamide meglumine. Flunixin meglumine Meglumine antimoniate Meglumine, chemicalland21.com v t e v ... Meglumine is a sugar alcohol derived from glucose that contains an amino group modification. It is often used as an excipient ... in pharmaceuticals and in conjunction with iodinated compounds in contrast media such as diatrizoate meglumine, ...
... came into medical use in 1946. It is on the World Health Organization's List of Essential Medicines. It ... Meglumine World Health Organization (2009). Stuart MC, Kouimtzi M, Hill SR (eds.). WHO Model Formulary 2008. World Health ... in German) "Meglumine antimoniate". Drug Information Portal. U.S. National Library of Medicine. Portal: Medicine (Webarchive ... Meglumine antimoniate is a medicine used to treat leishmaniasis. This includes visceral, mucocutaneous, and cutaneous ...
"Baxdela- delafloxacin meglumine tablet Baxdela- delafloxacin meglumine injection, powder, lyophilized, for solution". DailyMed ... "Delafloxacin meglumine". Drug Information Portal. U.S. National Library of Medicine. Portal: Medicine (Source attribution, CS1 ... The injectable form of delafloxacin is sold as the meglumine salt of the active ingredient and its United States Adopted Name, ... delafloxacin meglumine, reflects that; the injection formulation also includes EDTA and sulfobutylether-β-cyclodextrin. The ...
"Iothalamate meglumine". Drug Information Portal. U.S. National Library of Medicine. "Iothalamate sodium". Drug Information ... It is available in form of its salts, sodium iotalamate and meglumine iotalamate. It can be given intravenously or ... "Conray- iothalamate meglumine injection". DailyMed. 1 January 2021. Retrieved 23 February 2022. "Glofil-125- sodium iothalamate ... "Cysto-Conray II- iothalamate meglumine injection". DailyMed. 31 December 2020. Retrieved 23 February 2022. " ...
"Tafamidis meglumine Orphan Drug Designation and Approval". U.S. Food and Drug Administration. 3 May 2019. Archived from the ... It is marketed as a meglumine salt. It is slightly soluble in water. The laboratory of Jeffery W. Kelly at The Scripps Research ... "Tafamidis meglumine". Drug Information Portal. U.S. National Library of Medicine. Portal: Medicine (Source attribution, ... The FDA approved tafamidis meglumine based primarily on evidence from a clinical trial of 441 adult patients conducted at 60 ...
"Dotarem- gadoterate meglumine injection". DailyMed. Retrieved 29 August 2021. "Clariscan- gadoterate meglumine injection, ... and is used in form of the meglumine salt (gadoterate meglumine). The paramagnetic property of gadoteric acid reduces the T1 ... The meglumine salt it takes the form of crosses the blood brain barrier of tissue with abnormal vasculature, highlighting the ... "Gadoterate meglumine". Drug Information Portal. U.S. National Library of Medicine. Portal: Medicine (All articles with bare ...
meglumine antimoniate (Glucantim; manufactured by Aventis; available in Brazil, France and Italy), which is administered by ...
Urografin is a combination of the sodium and meglumine salts. The core structure is a popular one and numerous analogues exist ... Amersham Health (April 2006). "Hypaque (Diatrizoate Meglumine and Diatrizoate Sodium) injection, solution. Product label". ... Micromedex Healthcare Series (November 2010). "DIATRIZOATE MEGLUMINE/DIATRIZOATE SODIUM". DRUGDEX. Thomson Reuters (Healthcare ...
It was applied in form of its salt, meglumine iocarmate. It is not known to be marketed anywhere in the world in 2021. Schütte ... Van Dellen JR, Lipschitz R (October 1973). "Meglumine iocarmate (Dimer-X) ventriculography". Clinical Radiology. 24 (4): 449-52 ...
"Vyndaqel (tafamidis meglumine) NDA 202737" (PDF). U.S. Food and Drug Administration Center for Drug Evaluation and Research ...
This may include intravenous fluids and electrolytes to counteract the diarrhea; NSAIDs such as Banamine (flunixin meglumine); ...
Amersham Health (April 2006). "Hypaque (Diatrizoate Meglumine and Diatrizoate Sodium) injection, solution. Product label". ...
... meglumine Flunixin Meglumine For Veterinary Use Flunixin licensing in the UK provided by Norbrook (Articles with short ... It is often formulated as the meglumine salt. In the United States, it is regulated by the U.S. Food and Drug Administration ( ... Soma LR, Behrend E, Rudy J, Sweeney RW (November 1988). "Disposition and excretion of flunixin meglumine in horses". American ... Bryant CE, Farnfield BA, Janicke HJ (February 2003). "Evaluation of the ability of carprofen and flunixin meglumine to inhibit ...
... and as the meglumine salt for intravenous administration, which has the generic name estramustine phosphate meglumine. The INNM ... The molecular weight of EMP sodium is 564.3 g/mol, of EMP meglumine is 715.6 g/mol, of EMP is 520.4 g/mol, of estramustine is ... EMP is provided as the sodium or meglumine salt. EMP is similar as a compound to other estradiol esters such as estradiol ... As a result of these differences in molecular weights, EMP contains about 52%, EMP sodium about 48%, and EMP meglumine about 38 ...
Flunixin meglumine (Banamine) may help block the effects of toxemia. Mortality rate has been theorized to fall to 75% if ...
She has also worked with dengue diagnosis in Colombia, and participated in clinical trials evaluating the use of meglumine ... Castro MD, Cossio A, Velasco C, Osorio L (April 2017). "Risk factors for therapeutic failure to meglumine antimoniate and ... February 2012). "Noninferiority of miltefosine versus meglumine antimoniate for cutaneous leishmaniasis in children". The ...
These are drugs such as Flunixin meglumine (Banamine), Naproxen (Equiproxen), or Ketoprofen. This will help to bring the ...
... flunixin meglumine, and ketoprofen in horses". Journal of the American Veterinary Medical Association. 202 (1): 71-7. PMID ...
1993) Effects of large doses of phenylbutazone, flunixin meglumine, and ketoprofen in horses. J. Am. Vet. Med. Ass. 202, 71-77 ... Foreman, J. H.; Ruemmler, R. (2011). "Phenylbutazone and flunixin meglumine used singly or in combination in experimental ... although flunixin meglumine and firocoxib are also commonly used for orthopedic pain. Despite their widespread use, NSAIDs do ...
It is applied in form of its salts, ioxaglate meglumine and ioxaglate sodium. Uses include angiography (imaging of blood ...
It is used in form of its salts, ioxitalamate sodium and ioxitalamate meglumine. Wiggli U (January 1979). "[Clinical study of ...
Taenzer V, Volkhardt V (January 1979). "Double blind comparison of meglumine iotroxate (Biliscopin), meglumine iodoxamate ( ... Endobil), and meglumine ioglycamate (Biligram)". AJR. American Journal of Roentgenology. 132 (1): 55-8. doi:10.2214/ajr.132.1. ...
"The analgesic effect of ketoprofen for use in treating equine colic as compared to flunixin meglumine". Equine Pract. 13: 11-16 ...
To do an IVC, an iodine-containing dye (meglumine ioglycamate) is injected intravenously into the blood. The liver then removes ...
Coble, D.J., Taylor, D.K. and Mook, D.M. (2011). "Analgesic effects of meloxicam, morphine sulfate, flunixin meglumine, and ...
Coble, D.J., Taylor, D.K. and Mook, D.M. (2011). "Analgesic effects of meloxicam, morphine sulfate, flunixin meglumine, and ...
Coble DJ, Taylor DK, Mook DM (May 2011). "Analgesic effects of meloxicam, morphine sulfate, flunixin meglumine, and xylazine ...
... flunixin meglumine, ketoprofen, and meloxicam in dogs". American Journal of Veterinary Research. 68 (3): 258-264. doi:10.2460/ ...
... when cation A is the protonated form of the amino sugar meglumine the salt goes under the name "gadopentetate dimeglumine". It ...
Anti-inflammatory therapy is usually given both systemically, often in the form of flunixin meglumine, and topically, as ...
Effectiveness of meglumine antimoniate against L.tropica in a recently emerged focus of cutaneous leishmaniasis in Birjand, ...
Although cure rate of systemic meglumine antimoniate group was better the treatment with zinc sulfate is much easier, cheaper, ... and the second group was treated with systemic meglumine antimoniate (20 mg/kg/day intramuscularly for 20 days). ... more convenient in consumption, safer, and nearly close cure percentage to systemic meglumine antimoniate injections without ... Serious side effects resulting in treatment discounting occurred in only meglumine antimoniate group. ...
One hundred five patients were treated with meglumine antimoniate at a daily dose of 1 ampule per day (425 mg of Sb5+) until ... The main purpose of the present study was to investigate the response of chicleros ulcer to treatment with meglumine ... One hundred five patients were treated with meglumine antimoniate at a daily dose of 1 ampule per day (425 mg of Sb5+) until ... The main purpose of the present study was to investigate the response of chicleros ulcer to treatment with meglumine ...
Cysto-Conray® II (Iothalamate meglumine Injection USP 17.2%). *MD-Gastroview® (diatrizoate meglumine and diatrizoate sodium ... USA Products & Solutions Contrast Agents MD-Gastroview® (diatrizoate meglumine and diatrizoate sodium solution USP) ... MD-Gastroview® (diatrizoate meglumine and diatrizoate sodium solution USP). Scroll Down for Important Safety Information ... MD-Gastroview® (Diatrizoate Meglumine and Diatrizoate Sodium Solution) is indicated for radiographic examination of segments of ...
Systemic meglumine antimoniate in acute cutaneous leishmaniasis: children versus adults. Am J Trop Med Hyg. 2011 Apr;84(4):539- ... Effectiveness of meglumine antimoniate against L. tropica in a recently emerged focus of cutaneous leishmaniasis in Birjand, ... Khatami A, Talaee R, Rahshenas M, Khamesipour A, Mehryan P, Tehrani S, et al.. Dressings combined with injection of meglumine ... Eastern Mediterranean Health Journal , All issues , Volume 21, 2015 , Volume 21, issue 4 , Effectiveness of meglumine ...
... flunixin meglumine and meloxicam in rats , Z. Paksoy, A. Kirbas , Agricultural Journals ... The objective of this study was to determine the suitability of carprofen, flunixin meglumine and meloxicam for use in ... Compared with the control, the administration of flunixin meglumine (double dose), carprofen (double dose) and meloxicam highly ... Evaluation of the contraceptive effects of carprofen, flunixin meglumine and meloxicam in rats ...
... for Gadoterate Meglumine. Available for instant download from Affygility Solutions. ... Gadoteric acid is administered as the meglumine salt, gadoterate meglumine, and is indicated for MRI of brain and brain stem, ... To order an OEL/ADE monograph for Gadoterate Meglumine, just click the ADD TO CART button. ...
The highest dose of tafamidis meglumine given to healthy volunteers in a ... The highest dose of tafamidis meglumine given to healthy volunteers in a clinical trial was 480 mg as a single dose. There was ... VYNDAQEL (tafamidis meglumine) and VYNDAMAX (tafamidis) contain tafamidis as the active moiety, which is a selective stabilizer ... VYNDAQEL 20-mg (tafamidis meglumine) soft gelatin capsules are yellow, opaque, oblong, and printed with "VYN 20" in red and ...
Flunixin Meglumine) Injectable, 50 mg/ml (100 ml) and other products can be found at EntirelyPets Rx, the #1 source for ... Home , Anti-Inflammatory , Vetameg (Flunixin Meglumine) Injectable , Vetameg (Flunixin Meglumine) Injectable, 50 mg/ml (100 ml) ... Home , Shop By Category , Pet Prescription Medication , Vetameg (Flunixin Meglumine) Injectable , Vetameg (Flunixin Meglumine) ... Home , Shop By Category , Anti-Inflammatory , Vetameg (Flunixin Meglumine) Injectable , Vetameg (Flunixin Meglumine) Injectable ...
I am interested in your product Flunixin Meglumine Supplier. Verification:. 1 + 8 = ? ...
Fresenius Kabi has begun selling gadoterate meglumine injection, USP, a bioequivalent substitute for Guerbets contrast agent ... FDA indicates gadoterate meglumine injection as a gadolinium-based contrast agent (GBCA) for intravenous use with MRI in ... Gadoterate meglumine has the strongest atomic bond between gadolinium and chelate relative to other GBCAs. The strong bond ... In 2020, Guerbet announced that it had won FDA approval to manufacture gadoterate meglumine at a Raleigh, North Carolina ...
Florfluject®-It is indicated for the treatment of bovine respiratory disease complex (BRD) associated with Mannheimia haemolytica, Pasteurella multocida
Copy] Flunixin Meglumine. Function Antipyretic Analgesics Dosage Form Injection Animal Type Cattle, Fowl, Horse, Other Special ... Flunixin Meglumine. Function Antipyretic Analgesics Dosage Form Injection Animal Type Cattle, Fowl, Horse, Other Special ... Composition Flunixin meglumine Specification 10ml Original Dezhou, China Sample Available MOQ 1 kg Certificate GMP OEM Accept ... Composition Flunixin meglumine Specification 10ml Original Shandong, China Sample Available MOQ 1 Carton Certificate GMP OEM ...
Flunixin Meglumine Injection Veterinary. Flunixin Meglumine Injection Veterinary - Manufacturers, Suppliers, Factory. Sticking ... Flunixin Meglumine.We warmly welcome friends from all walks of life to seek mutual cooperation and create a more brilliant and ...
3 Meglumine adenosine cyclophosphate formulations found. Discover high-quality products from GMP-approved factories worldwide. ... meglumine adenosine cyclophosphate Solution for injection 2ml/30mg ; 5ml/60mg ; 10ml/150mg ...
We, MARUTI CHEMICALS one of the prominent leading Manufacturer, Supplier and Exporter of White Meglumine API based In Yogeshwar ...
No adverse effects were observed with flunixin meglumine administration for all routes. Flunixin meglumine was administered at ... Six mature swine (121-168 kg) were administered an IV, IM, or PO dose of flunixin meglumine at a target dose of 2.2  ... No adverse effects were observed with flunixin meglumine administration for all routes. Flunixin meglumine was administered at ... Table 1 Mean (± SD, n = 6) flunixin meglumine plasma concentrations (ng ml-1) after a single intravenous (IV), intramuscular ( ...
N-Methyl glucamine Antimoniate / MEGLUMINE ANTIMONIATE [CAS: 133-51-7]
Hebei Joycome Pharmaceutical Co., Ltd. is a veterinary pharmaceutical product development and manufacturing company founded in 2000 in Shijiazhuang Hebei
Meglumine antimoniate. *Sodium stibogluconate Other medicines that may be used include:. *Amphotericin B ...
In group B (meglumine antimoniate group), 62% were males, while 38% were females (p=0.63). The mean age was 32.81 years±12.09 ... COMPARISON OF EFFICACY OF MILTEFOSINE VERSUS MEGLUMINE ANTIMONATE IN THE TREATMENT OF CUTANEOUS LEISHMANIASIS Authors. * Noor ... cutaneous leishmaniasis, miltefosine, meglumine antimonate, efficacy Abstract. Background: Cutaneous Leishmaniasis is a morbid ... Meglumine antimoniate is more effective than sodium stibogluconate in the treatment of cutaneous leishmaniasis. J Dermatolog ...
Liquid Flunixim Meglumine Injection. 1 - 5 USD USD ($) Get latest price. *MOQ: 5000 Pack ...
After the diagnosis of feline leishmaniosis (FeL) was made, allopurinol and meglumine antimoniate were started and led to quick ... Long-term follow-up of a case of feline leishmaniosis treated with a combination of allopurinol and meglumine antimoniate. ...
Iohexol, loxaglate, meglumine diatrizoate, sodium indigotindisulfonate23 Corticosteroids. Betamethasone, hydrocortisone23 ...
Health Canada list representing substances and formulations which have been assessed on the basis of an application to market or further to promotion of products for medicinal purposes where safety and efficacy for such purposes have not been established
... gadoterate meglumine). Includes common and rare side effects information for consumers and healthcare professionals. ... Generic Name: gadoterate meglumine. Medically reviewed by Drugs.com. Last updated on Jan 21, 2020. ...
  • Gadoteric acid is administered as the meglumine salt, gadoterate meglumine, and is indicated for MRI of brain and brain stem, for blood-brain barrier disruption or abnormal vascularity. (affygility.com)
  • Fresenius Kabi has begun selling gadoterate meglumine injection, USP, a bioequivalent and therapeutic equivalent substitute for Guerbet's contrast agent Dotarem. (pharmaceuticalprocessingworld.com)
  • Fresenius Kabi is pleased to expand our contrast agent portfolio and our support for the radiology community with the launch of gadoterate meglumine injection, USP," said John Ducker, president and CEO of Fresenius Kabi USA, in a news release. (pharmaceuticalprocessingworld.com)
  • Contrast agents are vital to patient diagnosis, and the addition of Fresenius Kabi gadoterate meglumine will provide hospitals and clinics across the U.S. with more high-quality choices to support patient care. (pharmaceuticalprocessingworld.com)
  • FDA indicates gadoterate meglumine injection as a gadolinium-based contrast agent (GBCA) for intravenous use with MRI in intracranial, spine and associated tissues in adult and pediatric patients. (pharmaceuticalprocessingworld.com)
  • Gadoterate meglumine has the strongest atomic bond between gadolinium and chelate relative to other GBCAs. (pharmaceuticalprocessingworld.com)
  • In 2020, Guerbet announced that it had won FDA approval to manufacture gadoterate meglumine at a Raleigh, North Carolina facility. (pharmaceuticalprocessingworld.com)
  • Efficacy of Combined Intralesional Meglumine Antimoniate and Cryotherapy Versus Cryotherapy alone for the Treatment of Cutaneous Leishmaniasis. (edu.pk)
  • Silva, Júnior AT, Senna MC, Rabello A, Cota1 G. Intralesional meglumine antimoniate for the treatment of localised cutaneous leishmaniasis: a retrospective review of a Brazilian referral centre. (edu.pk)
  • Successful treatment of cutaneous leishmaniasis with intralesional meglumine antimoniate: A case series. (edu.pk)
  • The standard treatment remains intralesional meglumine antimoniate. (cdlib.org)
  • Fourteen patients with a total of 84 lesions received national standard treatment of weekly intralesional meglu- mine antimoniate with biweekly cryotherapy, or daily intramuscular meglumine antimoniate (20 mg/kg/day for 14 days), and topical Lip-AmB 0.4% twice daily for 28 days. (who.int)
  • Thirty patients with a total of 68 lesions received national stand- ard treatment of weekly intralesional meglumine antimoniate (to blanch around the lesion) and biweekly cryotherapy. (who.int)
  • Randomised controlled trial to determine the efficacy of thermotherapy in comparison with intralesional meglumine antimoniate to treat cutaneous leishmaniasis in an operational setting in Syria. (who.int)
  • The study will compare two treatments for cutaneous leishmaniasis: intralesional meglumine antimoniate (IL MA) and thermotherapy. (who.int)
  • The purpose of this study was to investigate comparison between oral zinc sulfate and meglumine antimoniate in the treatment of cutaneous leishmaniasis (CL). (hindawi.com)
  • Response of cutaneous leishmaniasis (chiclero's ulcer) to treatment with meglumine antimoniate in Southeast Mexico. (ajtmh.org)
  • This study identified the infecting Leishmania species and evaluated the results of meglumine antimoniate (Glucantime®) therapy in a new focus of cutaneous leishmaniasis in Birjand, eastern Islamic Republic of Iran. (who.int)
  • Purpose of study was to compare the efficacy of miltefosine and meglumine antimoniate in the treatment of cutaneous Leishmaniasis. (edu.pk)
  • Meglumine antimoniate is more effective than sodium stibogluconate in the treatment of cutaneous leishmaniasis. (edu.pk)
  • Noninferiority of miltefosine versus meglumine antimoniate for cutaneous leishmaniasis in children. (edu.pk)
  • Function Antipyretic Analgesics Dosage Form Injection Animal Type Cattle, Fowl, Horse, Other Special Breeding Animals, Pets, Pig, Sheep Place of Origin Dezhou, China (Mainland) Brand Name Jiulong Model Number 10ml/vial Appearance Colorless to slight yellow transparent liquid Composition Flunixin meglumine Specification 10ml Original Dezhou, China Sample Available MOQ 1 kg Certificate GMP OEM Accept Product Description Flunixin Meglumine Injection Main Compositi. (jiulonghxyy.com)
  • Sticking to the belief of "Creating products of high quality and making friends with people from all over the world", we always put the interest of customers in the first place for 20% Tilmicosin , 30% Tilmicosin Injection , 5% Flunixin Meglumine .We warmly welcome friends from all walks of life to seek mutual cooperation and create a more brilliant and splendid tomorrow. (jiulongpharmaceutical.com)
  • Flunixin-meglumine (FM) is approved in the US as an intramuscular (IM) injection in swine, and is available for intravenous (IV) and oral (PO) administration in other species [ 11 ]. (biomedcentral.com)
  • No adverse effects were observed with flunixin meglumine administration for all routes. (biomedcentral.com)
  • Serious side effects resulting in treatment discounting occurred in only meglumine antimoniate group. (hindawi.com)
  • Although cure rate of systemic meglumine antimoniate group was better the treatment with zinc sulfate is much easier, cheaper, more convenient in consumption, safer, and nearly close cure percentage to systemic meglumine antimoniate injections without serious side effect. (hindawi.com)
  • In group B (meglumine antimoniate group), 62% were males, while 38% were females (p=0.63). (edu.pk)
  • MD-Gastroview ® (Diatrizoate Meglumine and Diatrizoate Sodium Solution) is indicated for radiographic examination of segments of the gastrointestinal tract (esophagus, stomach, proximal small intestine, and colon). (guerbet.com)
  • A bottle of Gastrografin brand Diatrizoate Meglumine and Diatrisoate Sodium (lemon flavored). (theodoregray.com)
  • Treatment-cycle costs range from US$ 30 (for generic sodium stibogluconate) to US$ 120 (for meglumine antimonate) or US$ 150 (for sodium stibogluconate). (who.int)
  • Six mature swine (121-168 kg) were administered an IV, IM, or PO dose of flunixin meglumine at a target dose of 2.2 mg/kg in a cross-over design with a 10 day washout period between treatments. (biomedcentral.com)
  • Flunixin meglumine has been used exclusively within the veterinary community and is labeled for use in the U.S. for beef cattle, dairy cattle, horses and swine [ 16 ]. (biomedcentral.com)
  • Flunixin Meglumine is labeled for pyrexia control associated with swine respiratory disease at 2.2 mg/kg dose administered IM [ 17 ]. (biomedcentral.com)
  • One hundred five patients were treated with meglumine antimoniate at a daily dose of 1 ampule per day (425 mg of Sb5+) until healing. (ajtmh.org)
  • Treatment groups were administered carprofen (10 mg/kg, single or double dose, s.c .), flunixin meglumine (5 mg/kg, single or double dose, i.m .) and meloxicam (2 mg/kg, a single dose, s.c .) on the third day after mating. (agriculturejournals.cz)
  • The highest dose of tafamidis meglumine given to healthy volunteers in a clinical trial was 480 mg as a single dose. (pfizermedicalinformation.com)
  • Flunixin meglumine was administered at an actual mean dose of 2.21 mg/kg (range: 2.05-2.48 mg/kg) IV, IM and PO. (biomedcentral.com)
  • The first group was treated with oral zinc sulfate (10 mg/kg/day during 45 days period), and the second group was treated with systemic meglumine antimoniate (20 mg/kg/day intramuscularly for 20 days). (hindawi.com)
  • Systemic meglumine antimoniate is the initial therapy for 25 patients. (cdlib.org)
  • The objective of this study was to determine the suitability of carprofen, flunixin meglumine and meloxicam for use in emergency contraception. (agriculturejournals.cz)
  • In conclusion, this study indicates that carprofen, flunixin meglumine and meloxicam treatment cause a decline in implantation rate in rats. (agriculturejournals.cz)
  • Banamine (flunixin meglumine), Metacam (meloxicam), or carprofen. (ratguide.com)
  • Each ml of Banamine-S Injectable Solution contains flunixin meglumine equivalent to 50 mg flunixin. (valleyvet.com)
  • The main purpose of the present study was to investigate the response of chiclero's ulcer to treatment with meglumine antimoniate. (ajtmh.org)
  • Meglumine antimoniate treatment is well tolerated with no side-effects. (cdlib.org)
  • In animals where the owners did not authorize the surgery, treatment was instituted with sulfadoxine and flunixim meglumine. (ufrgs.br)
  • Flunixin meglumine is used to relieve pain and inflammation in horses and cattle and for its antipyretic properties. (entirelypetspharmacy.com)
  • The recommended dosage is either VYNDAQEL 80 mg (four 20-mg tafamidis meglumine capsules) orally once daily or. (pfizermedicalinformation.com)
  • After the diagnosis of feline leishmaniosis (FeL) was made, allopurinol and meglumine antimoniate were started and led to quick and complete clinical improvement. (bvsalud.org)
  • Common enemas include barium and diatrizoate meglumine. (medscape.com)
  • This study identified the infecting Leishmania species and evaluated the results of meglumine antimoniate (Glucantime®) therapy in a new focus of cutaneous leishmaniasis in Birjand, eastern Islamic Republic of Iran. (who.int)
  • Treatment of leishmaniasis in dogs, the domestic reservoir of L. infantum, with meglumine antimoniate (Glucantime) is a common practice in many Mediterranean countries. (nih.gov)
  • A study was therefore carried out to test the comparative susceptibility to meglumine antimoniate of L. infantum stocks isolated from four naturally-infected dogs, before (BT) and after treatment (AT) with three to six courses of the drug, and used to infect Balb/c mice. (nih.gov)
  • Each AT stock was between eight and 41 times more resistant to meglumine antimoniate than the BT stock from the same dog, in terms of the ratios of the AT ED50 values to the corresponding BT values, which were calculated as indices of resistance. (nih.gov)
  • The patient was treated with meglumine antimoniate that cured the lesion in a month post-treatment. (scielo.br)
  • 2017). Leishmania infantum exerts immunomodulation in canine Kupffer cells reverted by meglumine antimoniate . (up.pt)
  • Pentavalent antimonials (sodium stibogluconate and meglumine antimoniate) have been used as a first-line therapy for the last 70 years around the world.We report a case of a 1-year-old boy with two small yellowish papules mimicking juvenile xantogranuloma diagnosed with cutaneous leishmaniasis after a biopsy. (cdlib.org)
  • The activity of azithromycin against Leishmania (Viannia) braziliensis and Leishmania (Leishmania) amazonensis was evaluated in golden hamsters infected through footpad injections of metacyclic promastigotes, and compared with untreated controls and animals treated with meglumine antimoniate. (jefferson.edu)
  • For infections due to Leishmania (Viannia) braziliensis, azithromycin demonstrated significant activity relative to untreated controls, but inferior to meglumine antimoniate, for controlling lesion size. (jefferson.edu)
  • The dosage and duration of treatment with meglumine antimoniate (Glucantime ®) were consistent with what advocates the Ministry of Health. (unifesp.br)
  • Cost-effectiveness of meglumine antimoniate versus miltefosine caregiver DOT for the treatment of pediatric cutaneous leishmaniasis. (uchicago.edu)
  • Conclusion: In the present study, treatment failure was found in some confirmed CL patients treated with meglumine antimoniate. (ac.ir)
  • Patients with confirmed CL disease receive one of the treatments recommended by the Colombian Ministry of Social Protection: meglumine antimoniate or miltefosine, for 20 or 28 days respectively. (who.int)
  • What is Clariscan (gadoterate meglumine), and how is it used? (medicinenet.com)
  • Clariscan (gadoterate meglumine) is a prescription medicine called a gadolinium-based contrast agent (GBCA). (medicinenet.com)
  • Specific drug interaction studies with gadoterate meglumine have not been conducted. (medicinenet.com)
  • Clariscan (gadoterate meglumine) is a radioactive contrast agent injected into people prior to an MRI scan. (medicinenet.com)
  • Gadoterate meglumine is a contrast agent that has magnetic properties. (emedicinehealth.com)
  • Gadoterate meglumine is used to help diagnose certain disorders of the brain and spine ( central nervous system ). (emedicinehealth.com)
  • Gadoterate meglumine may also be used for purposes not listed in this medication guide. (emedicinehealth.com)
  • What are the possible side effects of gadoterate meglumine (Clariscan, Dotarem)? (emedicinehealth.com)
  • Some side effects of gadoterate meglumine may occur up to several days after injection. (emedicinehealth.com)
  • Gadoterate meglumine can cause a life-threatening condition in people with advanced kidney disease . (emedicinehealth.com)
  • What is the most important information I should know about gadoterate meglumine (Clariscan, Dotarem)? (emedicinehealth.com)
  • What should I discuss with my healthcare provider before receiving gadoterate meglumine (Clariscan, Dotarem)? (emedicinehealth.com)
  • Gadoterate meglumine can stay in your body for months or years after you receive this medicine. (emedicinehealth.com)
  • You should not receive gadoterate meglumine if you are allergic to it. (emedicinehealth.com)
  • Gadoterate meglumine is given as an infusion into a vein. (emedicinehealth.com)
  • Since gadoterate meglumine is used only during your MRI, you will not be on a dosing schedule. (emedicinehealth.com)
  • What should I avoid after receiving gadoterate meglumine (Clariscan, Dotarem)? (emedicinehealth.com)
  • What other drugs will affect gadoterate meglumine (Clariscan, Dotarem)? (emedicinehealth.com)
  • Other drugs may affect gadoterate meglumine, including prescription and over-the-counter medicines, vitamins , and herbal products. (emedicinehealth.com)
  • Your doctor can provide more information about gadoterate meglumine. (emedicinehealth.com)
  • These highlights do not include all the information needed to use GADOTERATE MEGLUMINE INJECTION safely and effectively. (nih.gov)
  • See full prescribing information for GADOTERATE MEGLUMINE INJECTION. (nih.gov)
  • Gadoterate Meglumine Injection is a gadolinium-based contrast agent indicated: for intravenous use with magnetic resonance imaging (MRI) in brain (intracranial), spine and associated tissues in adult and pediatric patients (including term neonates) to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity. (nih.gov)
  • Adult and pediatric patients: The recommended dose of Gadoterate Meglumine Injection is 0.2 mL/kg (0.1 mmol/kg) body weight administered as an intravenous bolus injection at a flow rate of approximately 2 mL/second for adults and 1 to 2 mL/second for pediatric patients (including term neonates). (nih.gov)
  • Gadoterate Meglumine Injection 0.5 mmol per mL contains 376.9 mg per mL of gadoterate meglumine and is available in single dose vials. (nih.gov)
  • Clinically important hypersensitivity reactions to Gadoterate Meglumine Injection. (nih.gov)
  • Learn Gadoterate Meglumine for Use with Magnetic Resonance Imaging (Dotarem)- Multum Fleet Management Gain real-time insight or historical playback of vehicles, including location, vehicle fault codes, driver behavior alerts, and fuel usage. (clashofmagic.xyz)
  • Learn more What our customers are saying Tract Systems software allowed us to increase our operational efficiencies by moving our traditional paper based processes into a real time, Gadoterate Meglumine for Use with Magnetic Resonance Imaging (Dotarem)- Multum based application. (clashofmagic.xyz)
  • Dietary SupplementUrinary AcidificationScurvyCerner MultumCerner Dotarm Provided and Reviewed by Cerner MultumwarningsWhat is the most important information I should know about Ascorbic Acid (Vitamin C). You should not use ascorbic acid if you have ever Dotarem (Gadoterate Meglumine for Use with Magnetic Resonance Imaging)- FDA an allergic reaction to a vitamin C supplement. (alaskasworld.xyz)
  • Do Dotarem (Gadoterate Meglumine for Use with Magnetic Resonance Imaging)- FDA use in larger or smaller amounts Imsging)- for longer than recommended. (alaskasworld.xyz)
  • The results showed 80 percent of surveyed pediatric hospitals used macrocyclic contrast agents and within the last year, 58 percent switched their agent, most commonly to gadoterate meglumine. (diagnosticimaging.com)
  • Of these hospitals, 83 percent would switch to gadoterate meglumine. (diagnosticimaging.com)
  • The researchers concluded many pediatric hospitals have switched to or plan to switch to a more stable macrocyclic MR contrast agent, most commonly gadoterate meglumine based on the discovery of the presence of brain gadolinium deposition. (diagnosticimaging.com)
  • 12. Does Gadoterate Meglumine Cause Gadolinium Retention in the Brain of Children? (nih.gov)
  • Soyer P, Dohan A, Patkar D, Gottschalk A. Observational study on the safety profile of gadoterate meglumine in 35,499 patients: The SECURE study. (medscape.com)
  • Gadoterate meglumine is increasingly being used by radiology departments seeking stable MRI contrast agents in pediatric hospitals, according to a survey conducted to assess the current state of gadolinium-based contrast agent (GBCA) use. (appliedradiology.com)
  • Nearly 60% of the pediatric radiology department chairpersons reported that their hospital had switched from their GBCA, primarily to gadoterate meglumine, a more stable macrocyclic MR contrast agent. (appliedradiology.com)
  • An additional 23% were considering switching to a macrocyclic GBCAs in 2017, with the majority considering gadoterate meglumine. (appliedradiology.com)
  • To prospectively compare in healthy rats the effect of multiple injections of macrocyclic (gadoterate meglumine) and linear (gadodiamide) gadolinium-based contrast agents (GBCAs) on T1-weighted signal intensity in the deep cerebellar nuclei (DCN), including the dentate nucleus. (sigmaaldrich.com)
  • gadoterate meglumine, gadopentetate dimeglumine, and gadobenate dimeglumine) in in vitro levels. (scilit.net)
  • Tafamidis meglumine and tafamidis are indicated for cardiomyopathy caused by transthyretin-mediated amyloidosis (ATTR-CM) in adults. (medscape.com)
  • Efficacy of tafamidis was shown in a clinical trial of 441 patients randomized to receive tafamidis meglumine or a placebo. (medscape.com)
  • Comments: Tafamidis and tafamidis meglumine products are not substitutable on a per mg basis. (healthguv.com)
  • Presurgical medications administered included flunixin meglumine, 0.5 mg/kg SID IM (Banamine®, Schering-Plough Animal Health Corp. Union, NJ 07083 USA) and ceftiofur sodium, 1.1 mg/kg IM SID (Naxcel®, Pharmacia & Upjohn Co. Animal Health Division, 7000 Portage Road, Kalamazoo, MI 49001 USA) for the 2 days prior to surgery. (vin.com)
  • Objective: Check the general characteristic of VL patients, the criteria used for diagnosis, possible side effects to meglumine antimonite (Glucantime®) and blood pressure before and after the treatment. (unifesp.br)
  • Method: Observational transversal descriptive study with evaluation of 89 patients treated with meglumine antimonite (Glucantime®) in HEHA/Maceio/Brazil, in the period of May/2006 to December/2009. (unifesp.br)
  • For these, we collected data concerning to age, gender, place of origin, diagnostic method, side effects to meglumine antimonite (Glucantime®), hospitalization period and length of treatment and cumulative dose until side effects. (unifesp.br)
  • Each 30-gram syringe of Flunazine Paste contains flunixin meglumine equivalent to 1500 mg flunixin. (medi-vet.com)
  • Oral Tablets: 450 mg delafloxacin (equivalent to 649 mg delafloxacin meglumine). (nih.gov)
  • 2018. Comparison of etomidate, benzocaine, and MS222 anesthesia with and without subsequent flunixin meglumine analgesia in African clawed frogs (Xenopus laevis). (awionline.org)
  • Na segunda fase do estudo foi realizada a avaliação da analgesia promovida pela dipirona em 15 equinos submetidos ao procedimento de orquiectomia eletiva, na qual um dos grupos recebeu no pósoperatório, dipirona 15mg/Kg, a cada 12 horas e outro grupo recebeu flunixin meglumine 1,1mg/Kg a cada 24 horas, ambos pela via intravenosa. (usp.br)
  • In the second phase of the study, the assessment was conducted to evaluate the analgesia provided by dipyrone in 15 horses submitted to elective orchiectomy procedure, in which one of the groups received, postoperatively, dipyrone 15mg/kg, every 12 hours, and the other group received flunixin meglumine 1.1 mg/kg every 24 hours, both intravenously. (usp.br)
  • Available at http://www.who.int/leishmaniasis/disease_epidemiology/en/ . (medscape.com)
  • Flunixin meglumine is a potent nonnarcotic, nonsteroidal, analgesic agent with anti-inflammatory and antipyretic activity. (medi-vet.com)
  • By combining the antibiotic florfenicol with the non-steroidal anti-inflammatory (NSAID) flunixin meglumine, RESFLOR GOLD helps treat BRD and the fever that often accompanies it. (merck-animal-health-usa.com)
  • These drugs can be provided in two formulations: meglumine antimonite and sodium stibogluconate. (atlanticfinancialmanagement.co.uk)
  • From the patients that were treated with meglumine antimonite, 3 (3.37%) died, 12 (13.48%) showed side effects and 74 (83.14%) were healed. (unifesp.br)
  • If possible use with meglumine antimonate, if not use allopurinol alone at 10 mg/kg orally twice daily. (medi-vet.com)
  • Merck Animal Health is shipping much needed product, ZuprevoTM and Resflor® (florfenicol and flunixin meglumine), to help address the growing health issues in these areas. (thedairysite.com)
  • Medicines web site http://www.who.int/medicines/areas/quality_assurance/en/index.html. (who.int)
  • 2019. Effects of transdermal flunixin meglumine on experimentally induced lameness in adult dairy cattle. (iastate.edu)
  • In case of allergic response, administer flunixin meglumine and/or epinephrine. (us.com)
  • Meglumine can form salts with some drugs to increase the solubility of the drug. (haihangindustry.com)
  • Flunixin meglumine (FM) was investigated for the effectiveness of plasma, oral fluid, and urine concentrations to predict tissue residue depletion profiles in finishing-age swine, along with the potential for untreated pigs to acquire tissue residues following commingled housing with FM-treated pigs. (iastate.edu)